LRMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Larimar Therapeutics Inc (LRMR) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock has positive momentum in the pre-market, bullish moving averages, strong analyst ratings with increased price targets, and a recent $100M capital raise. Despite the lack of recent news or congress trading data, the company's financial performance shows significant improvement in net income and EPS YoY. The options data also indicates a bullish sentiment with a low Put-Call ratio. While the stock may experience short-term volatility, the long-term outlook appears favorable.
The stock is showing bullish moving averages (SMA_5 > SMA_20 > SMA_200), a positive MACD histogram of 0.0229, and neutral RSI at 40.003. The pre-market price is $4.86, up 1.89%. Key support and resistance levels are S1: 4.89, Pivot: 5.366, and R1: 5.842.
Analysts have raised price targets (Wedbush: $12, Citi: $
and maintain positive ratings.
The company recently raised $100M following a Breakthrough Therapy designation for nomlabofusp in Friedreich's ataxia.
Improved financial performance with significant YoY growth in net income and EPS.
No recent news or congress trading data.
FDA decisions remain a concern for investors, as noted by analysts.
In Q3 2025, the company reported a net income increase of 207.84% YoY to -$47.71M and an EPS improvement of 154.17% YoY to -0.61. Revenue and gross margin remained at 0.
Analysts are positive on the stock. Wedbush raised the price target to $12 and Citi to $14, both maintaining strong ratings. Analysts are encouraged by the company's active dialogue with the FDA and its recent capital raise.
